Recursion Pharmaceuticals financials
$4.03+8.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $6.5M | $35.5M | $5.2M | $19.2M | $14.7M | $4.5M | $26.1M | $14.4M | $13.8M | $10.9M | $10.5M |
| Gross profit | -$3.8M | -$6.0M | $21.3M | -$9.5M | -$938.0K | -$7.1M | -$8.2M | $14.0M | $5.2M | $2.6M | $1.0M | -$344.0K |
| Gross margin | −49.8% | −93.0% | 59.8% | −183.8% | −4.9% | −48.0% | −181.4% | 53.7% | 36.2% | 19.1% | 9.3% | −3.3% |
| Operating income | -$135.0M | -$128.5M | -$108.3M | -$172.2M | -$176.2M | -$191.4M | -$183.8M | -$98.4M | -$100.5M | -$96.3M | -$98.9M | -$99.5M |
| Net income | -$131.0M | -$117.5M | -$108.1M | -$162.3M | -$171.9M | -$202.5M | -$178.9M | -$95.8M | -$97.5M | -$91.4M | -$93.0M | -$93.0M |
| Net margin | −1708.0% | −1815.6% | −304.2% | −3135.3% | −894.2% | −1373.3% | −3935.5% | −367.5% | −676.6% | −662.4% | −853.9% | −883.1% |
| Diluted EPS | $-0.25 | $-0.22 | $-0.21 | $-0.36 | $-0.41 | $-0.50 | $-0.53 | $-0.34 | $-0.40 | $-0.39 | $-0.42 | $-0.43 |
| EBITDA | -$116.8M | -$108.8M | -$88.9M | -$151.2M | -$152.4M | -$172.0M | -$170.8M | -$91.2M | -$91.6M | -$89.0M | -$98.9M | -$92.0M |
| Operating cash flow | -$105.9M | -$81.1M | -$46.1M | -$117.4M | -$76.4M | -$132.0M | -$115.4M | -$59.2M | -$82.2M | -$102.3M | -$74.1M | -$72.9M |
| Free cash flow | -$106.0M | -$81.4M | -$47.3M | -$117.6M | -$79.6M | -$133.8M | -$116.7M | -$63.8M | -$83.4M | -$109.0M | -$76.1M | -$73.7M |
| Diluted shares | 532.5M | 529.3M | 522.7M | 447.0M | 417.4M | 402.8M | 336.0M | 282.6M | 242.2M | 236.0M | 224.1M | 214.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $545.7M | $654.5M | $743.3M | $659.8M | $525.1M | $500.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $14.2M | $16.4M | $18.7M | $20.8M | $22.9M | $25.0M |
| Total assets | $1.21B | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B |
| Total liabilities | $297.7M | $314.8M | $343.3M | $352.6M | $383.2M | $371.3M |
| Shareholders' equity | $915.0M | $1.02B | $1.13B | $1.05B | $919.1M | $933.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology